BioCentury
ARTICLE | Top Story

ASCO publishes its value framework

June 23, 2015 1:38 AM UTC

The American Society of Clinical Oncology published in the Journal of Clinical Oncology a Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) scored 42/100; it has a monthly drug acquisition cost of $7,523.88. Xtandi enzalutamide from Medivation Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. (Tokyo:4503) received a score of 32/130 and has a monthly cost of $8,494.91. The score for Jevtana cabazitaxel from Sanofi (Euronext:SAN; NYSE:SNY) plus prednisone was 16/130; its monthly cost is $10,699.43.

In first-line metastatic NSCLC, Tarceva erlotinib from Roche (SIX:ROG; OTCQX:RHHBY) and Astellas had a benefit score of 44/130; it has a monthly cost of $4,607.63. Avastin bevacizumab from Roche's Genentech Inc. unit received a score of 16/130 and has a monthly cost of $11,907.87. Two chemotherapy combinations, cisplatin plus Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY) and gemcitabine plus docetaxel, each received scores of 0/130. The combinations have monthly costs of $9,193.07 and $2,184.18, respectively. ...